

Comparison of supercritical fluid chromatographic methods to predict the skin permeability of pharmaceutical and cosmetic compounds

Grooten, Yasmine; Mangelings, Debby; Vander Heyden, Yvan

Published in:
Journal of Chromatography. A

DOI:
[10.1016/j.chroma.2023.463855](https://doi.org/10.1016/j.chroma.2023.463855)

Publication date:
2023

License:
CC BY-NC-ND

Document Version:
Accepted author manuscript

[Link to publication](#)

Citation for published version (APA):
Grooten, Y., Mangelings, D., & Vander Heyden, Y. (2023). Comparison of supercritical fluid chromatographic methods to predict the skin permeability of pharmaceutical and cosmetic compounds. *Journal of Chromatography. A*, 1692, 1-11. Article 463855. <https://doi.org/10.1016/j.chroma.2023.463855>

Copyright

No part of this publication may be reproduced or transmitted in any form, without the prior written permission of the author(s) or other rights holders to whom publication rights have been transferred, unless permitted by a license attached to the publication (a Creative Commons license or other), or unless exceptions to copyright law apply.

Take down policy

If you believe that this document infringes your copyright or other rights, please contact openaccess@vub.be, with details of the nature of the infringement. We will investigate the claim and if justified, we will take the appropriate steps.

1 **Comparison of supercritical fluid chromatographic methods to predict the**
2 **skin permeability of pharmaceutical and cosmetic compounds**

3 Yasmine Grooten, Debby Mangelings, Yvan Vander Heyden*

4

5

6 Vrije Universiteit Brussel (VUB), Department of Analytical Chemistry, Applied Chemometrics and Molecular
7 Modelling, Laarbeeklaan 103, B-1090 Brussels, Belgium

8 *: Corresponding author

9

10 *E-mail addresses:* yasmine.grooten@vub.be (Y. Grooten), debby.mangelings@vub.be (D.
11 Mangelings), yvan.vander.heyden@vub.be (Y. Vander Heyden)

12 **Abstract**

13 Supercritical fluid chromatography (SFC) was explored as an alternative for liquid chromatography to
14 predict the skin permeability of pharmaceutical and cosmetic compounds. Nine dissimilar stationary
15 phases were applied to screen a test set of 58 compounds. The experimental retention factors ($\log k$),
16 in addition to two sets of theoretical molecular descriptors, were applied to model the skin
17 permeability coefficient. Different modelling approaches, i.e. multiple linear regression (MLR) and
18 partial least squares (PLS) regression, were used. In general, the MLR models performed better than
19 the PLS models for a given descriptor set. The results obtained on a cyanopropyl (CN) column
20 provided the best correlation with the skin permeability data. The retention factors obtained on this
21 column were included in a simple MLR model, together with the octanol-water partition coefficient
22 and the number of atoms ($r^2 = 0.81$, RMSEC = 0.537 or 20.5% and RMSECV = 0.580 or 22.1%). The
23 overall best MLR model included the chromatographic descriptor from a phenyl column and 18
24 descriptors ($r^2 = 0.98$, RMSEC = 0.167 or 6.2% and RMSECV = 0.238 or 8.9%). This model showed
25 a good fit, on top of very good predictive features. However, stepwise MLR models with a reduced
26 complexity could also be determined, with the best performance parameters obtained with the CN-
27 column based retention and eight descriptors ($r^2 = 0.95$, RMSEC = 0.282 or 10.7% and RMSECV =
28 0.353 or 13.4%). SFC thus provides a suitable alternative to the liquid chromatographic techniques
29 previously applied to model the skin permeability.

30 **Keywords**

31 Skin permeability, quantitative retention-activity relationship models, quantitative structure-activity
32 relationship models, supercritical fluid chromatography

33 1. Introduction

34 The skin plays an important role in many functions of the human body, such as preserving
35 homeostasis and forming a barrier between the external and internal environment, but also as a sensory
36 organ. It consists of three main layers, i.e. the epidermis, dermis and subcutaneous layer, along with
37 the appearance of several skin appendages (sweat glands, sebaceous glands and hair follicles) [1]. The
38 stratum corneum, the outermost layer of the epidermis, is the most important permeation barrier of the
39 skin. Its structure is often referred to as a ‘bricks and mortar’ model, built with keratin-packed
40 corneocytes surrounded by a matrix of lipid bilayers [2]. These hydrophobic lipids are mostly
41 composed of ceramides, cholesterol and long-chain free fatty acids. When the skin is exposed to
42 chemical, pharmaceutical or cosmetic compounds, passive diffusion through the skin (and possibly
43 into the systemic circulation) can occur. The skin permeability coefficient K_p (expressed in cm/s or
44 cm/h) indicates the rate at which a compound passes the skin [3]. This value can be estimated through
45 *in-vivo* and *in-vitro* tests, of which, for some, guidelines with standardized procedures have been
46 provided [4]. However, drawbacks, such as ethical aspects, high variability and difficulties to
47 extrapolate from animal to human skin, on top of the European ban on animal testing of cosmetics,
48 have raised the need for alternative methods [4,5].

49 *In-silico* approaches may provide an alternative, applying quantitative structure-activity
50 relationship (QSAR) models, in which a biological activity (in this case, the skin permeability) is
51 modelled as a function of physicochemical and/or structural properties of compounds (expressed by
52 theoretical descriptors) [6–8]. Furthermore, these theoretical descriptors can be combined with one or
53 more experimental chromatographic descriptors. Retention on several reversed-phase liquid
54 chromatographic (RPLC) systems has been applied in this context to model the skin permeability of
55 compounds. Besides regular octadecyl columns [9], biomimicking systems have been applied to
56 resemble the skin structure. Immobilized artificial membrane (IAM) columns, which contain
57 phospholipid analogues (mostly phosphatidylcholine) covalently bound to the silica surface, have been
58 used to model $\log K_p$ [10–14]. Furthermore, other stationary phases containing skin components, such
59 as cholesterol [15,16], keratin [17] and collagen [18], have been applied for the same purpose.

60 Micellar liquid chromatography (MLC) is another important technique in modelling the skin
61 permeability. Micelles are formed when a surfactant, in the mobile phase, is above its critical micelle
62 concentration, resulting in a pseudo-phase with which solutes can interact [19]. The chromatographic
63 descriptors, obtained with either the anionic surfactant sodium dodecyl sulfate (SDS) or the nonionic
64 Brij-35 (for the latter the term biopartitioning micellar chromatography (BMC) has been defined),
65 have been used in skin permeability models [20–23]. Furthermore, thin-layer chromatography has
66 been explored recently to model skin permeability [24–26].

67 Supercritical fluid chromatography (SFC) increased in popularity over the last years because of
68 its many advantages. The mobile phase consists of a supercritical or subcritical fluid, which shows a
69 low viscosity and high diffusivity, allowing the application of higher flow rates and thus fast analyses
70 [27]. Most frequently, the non-toxic, non-polar and inert carbon dioxide (CO₂), which reaches its
71 supercritical state at a rather low temperature and pressure (31°C and 74 bar, respectively), is the main
72 compound in the mobile phase [28]. The polarity of CO₂ can be increased by the addition of more
73 polar modifiers, e.g. methanol, ethanol and acetonitrile. Because lower modifier fractions are needed
74 than in liquid chromatography (LC), lower solvent consumption is achieved [29]. As the stationary
75 phase, all types used in liquid chromatography (ranging from polar to non-polar) can be applied in
76 SFC. Furthermore, some, e.g. with a 2-ethylpyridine (2-EP) modification, were developed specifically
77 for SFC [30,31]. Column selection for method development is therefore often challenging.
78 Classification systems, indicating similarities and dissimilarities between stationary phases, may
79 provide a solution. West et al. [32] applied linear solvation energy relationship (LSER) models in this
80 context, characterizing column types in SFC by certain physicochemical properties. Galea et al. [33]
81 proposed a set of six dissimilar stationary phases (selected out of 27), suitable for method development
82 for pharmaceutical compounds in SFC. Selection was based on the application of the Kennard and
83 Stone algorithm on the retention-factor matrix from test set compounds and on the resulting principal
84 component analysis (PCA) plots.

85 In previous studies, we built skin-permeability predicting models using two sets of molecular
86 descriptors, and compared them to models containing both theoretical and chromatographic

87 descriptors obtained from various LC methods. The retention factors measured with an octadecyl
88 column showed to contribute little to improve the models containing only theoretical descriptors [34].
89 Afterwards, an MLC method was applied on the same column type, both on a particle-based and on a
90 monolithic column. Improvement of the models was noticed compared to the *in-silico* ones, with a
91 preference for the monolithic-column retention because of its speed [35]. Three additional methods
92 were further compared, i.e. on an IAM, a cholesterol-bonded (in HPLC), and a sub-2 μm C18 column
93 (in UHPLC). Although the best correlation between the retention factors and the skin permeability
94 coefficients was obtained for those from the IAM column, combining the UHPLC results with
95 theoretical descriptors provided a better model, on top of being a faster analysis [36].

96 The aim of this study was to evaluate a new approach to model skin permeability, i.e. by using
97 chromatographic descriptors obtained with SFC. To the best of our knowledge, this technique was not
98 yet applied in this context. Given the fast and ‘green’ properties of SFC, it may provide an improved
99 alternative to the descriptors previously obtained in HPLC and UHPLC. Several stationary phases
100 were tested in SFC, to assess their applicability in the context of skin permeability modelling. The
101 selection of the stationary phases was based on a set of dissimilar columns proposed by Galea et al.
102 [33,37], plus a cholesterol-bonded column (because of its link to the skin structure). The test set from
103 the previous studies, with 58 diverse pharmaceutical and cosmetic compounds, was analyzed. From
104 using a generic gradient on a limited number of compounds, the isocratic methanol fraction in the
105 mobile phase was determined on each column as the average fraction needed to elute the compounds
106 of a subset. This mobile phase was then applied isocratically to screen the entire test set. The retention
107 factors, and one of two sets of theoretical descriptors, from Vega ZZ and E-Dragon software,
108 respectively, were thereafter used to model the skin permeability coefficient, $\log K_p$. Both multiple
109 linear regression (MLR) and partial least squares (PLS) regression were applied, after which the best
110 models, containing the retention on one of the different stationary phases, were compared.
111 Furthermore, the best skin permeability models were compared to the models obtained from the
112 previous studies [34–36].

113 2. Materials and methods

114 2.1. Chemicals and reagents

115 CO₂ quality 4.5 (purity \geq 99.995%) was purchased from Messer (Sint-Pieters-Leeuw, Belgium).
116 HPLC grade methanol (MeOH) was from VWR Chemicals (Fontenay-sous-Bois, France). The test set
117 was composed of 58 compounds with different physicochemical and pharmaceutical properties,
118 comprising a relevant log *P* range (-1.13 to 4.45), equivalent to a pH dependent hydrophobicity log *D*
119 range from -1.86 to 4.31 (calculated with Chemicalize (Chemaxon, Budapest, Hungary) at the pH of
120 the skin, i.e. pH 5.5), and log *K_p* ranges from -5.52 to -0.24, taken from the literature [38–42] (see
121 **Table 1** for an overview). While log *P* takes into account the distribution of neutral species of a
122 compound in octanol and water, log *D* determines the ratio of both the neutral and ionized forms (=
123 microspecies) of the compound in octanol and water (taking the p*K_a* and specified pH into
124 consideration) as follows: $D = [\text{sum of concentration of microspecies}]_{\text{octanol}} / [\text{sum of concentration of}$
125 $\text{all microspecies}]_{\text{water}}$. The test set compounds were obtained from Bios Coutelier (Brussels, Belgium),
126 Certa (Braine-l'Alleud, Belgium), Diosynth (Oss, The Netherlands), Fluka (Neu-Ulm, Switzerland),
127 Merck (Darmstadt, Germany) and Sigma-Aldrich (Steinheim, Germany), with a purity of at least 95%.
128 Individual sample solutions of 0.1 mg/mL were prepared in MeOH. When no result was measured,
129 higher concentrations (0.25, 0.5, 0.75 and 1.0 mg/mL) were analyzed.

130 2.2. Instrumentation

131 The analyses were performed on an ACQUITY Ultra Performance Convergence Chromatography
132 (UPC²) instrument from Waters (Milford, MA, USA). The system consisted of a binary solvent
133 delivery pump, a convergence manager, an external ACQUITY column oven without active pre-
134 heating, an autosampler (with a fixed loop of 10 μ L) and a photodiode array (PDA) detector. The
135 sample compartment was kept at 10°C throughout the analyses. Empower 3 software (version 7.10,
136 Waters) was used for data collection and processing. The nine stationary phases tested are shown in
137 **Table 2**. They were obtained from Phenomenex (Torrance, CA, USA), Nacalai Tesque (Kyoto, Japan)
138 and Waters.

139 2.3. Gradient screening for isocratic mobile-phase composition determination

140 A generic gradient was applied on a selection of compounds (covering the log P range of the test set)
141 to determine the best MeOH fraction in the mobile phase for the isocratic screening of the entire test
142 set. The gradient starts with a mixture of CO₂ with 5% MeOH, which is increased to 40% in 10 min.
143 The latter fraction was held for 5 min, after which it was decreased again to 5% MeOH in 0.5 min. To
144 recondition the column, 5% MeOH was kept for 2 min, which results in a total run time of 17.5 min.
145 When the maximal allowable column pressure restricted the operating conditions, the upper gradient
146 limit was decreased (e.g. to 20% MeOH). The modifier fraction C_e at which each compound elutes
147 within the gradient can be calculated as:

$$148 \quad C_e = C_i + \frac{C_f - C_i}{t_G} (t_R - t_d - t_0) \quad (\text{Eq. 1})$$

149 in which C_i and C_f correspond to the initial and final modifier fractions in the gradient, respectively, t_G
150 is the gradient time, t_R the retention time of the analyzed compound, t_d the instrument dwell time and t_0
151 the column void time [43]. The average C_e value for all compounds was used to decide on the MeOH
152 fraction in the isocratic mobile phase.

153 *2.4. Experimental conditions*

154 The test set was analyzed isocratically, applying a mobile phase consisting of CO₂ and MeOH, of
155 which the fraction was determined from the gradient screening. A flow rate of 3.0 mL/min was
156 applied, except for the ACQUITY UPC² BEH column (sub-2 μm particles) for which the flow rate
157 was 1.5 mL/min. A backpressure of 150 bar and a temperature of 25°C were maintained. UV detection
158 was carried out at 220 nm. The injection volume was 10 μL for most columns, except for the
159 ACQUITY UPC² BEH column, where it was 2 μL. The compounds were injected in triplicate.
160 Retention factors (k) were determined as $(t_R - t_0)/t_0$, with the first disturbance of the baseline as t_0 .

161 *2.5. Data sources, software and data processing*

162 The skin permeability coefficients, originating from *in-vitro* tests, were obtained from a validated
163 database [38], and were extended with those of some additional relevant compounds [39–42]. It should
164 be noticed that combining permeability data from several references is not recommended. However,
165 because of their limited availability, it is often not possible to acquire large test sets from one source.
166 The Vega ZZ software (version 3.2.1.33) [44] provided a first set of molecular descriptors,

167 representing 21 physicochemical, geometrical and topological properties, such as the Virtual log P ,
168 number of atoms (*Atoms*), molecular weight and gyration radius. Additionally, the melting point from
169 PubChem was included in this descriptor set [45]. A second set of 1666 descriptors was acquired using
170 E-Dragon software [46]. The (nearly) constant descriptors were removed from this set, as well as the
171 highly correlated ($r > 0.95$, retaining the descriptor with the highest correlation to $\log K_p$), which
172 reduced the number of descriptors to 408.

173 MLR modelling with the Vega ZZ descriptors was performed using the ‘automatic linear
174 regression’ module in the Vega ZZ software. Descriptors, except the chromatographic, which
175 presented an $r^2 < 0.10$ with $\log K_p$ were excluded from the modelling. Furthermore, collinear
176 descriptors showing a variance inflation factor (VIF, calculated as $1/(1-r^2)$) above 5 were never
177 combined in the MLR models. The best models with one to seven descriptors, which included the
178 chromatographic descriptor, were compared.

179 Stepwise MLR and PLS modelling were carried out using m-files in MATLAB R2019b (The
180 Mathworks, Natick, MA, USA). With the stepwise MLR approach, models were built, alternating a
181 forward selection with a backwards deletion of descriptors, until the fit of the model was not further
182 enhanced by the addition or exclusion of descriptors. The descriptors in these models are shown in the
183 order they were selected during the stepwise approach. The best PLS model contained a number of
184 latent variables, which was selected based on the lowest root mean squared error of leave-one-out
185 cross validation.

186 All models were evaluated by their RMSECV and RMSEC (root mean squared error of cross
187 validation and calibration, respectively), which quantified their predictive abilities and fit,
188 respectively. The lower these values, the better the model. For both parameters, relative values to the
189 average $\log K_p$ are also shown, allowing an easier comparison of models built with different numbers
190 of compounds. Additionally, the determination coefficient r^2 between the predicted and experimental
191 $\log K_p$ values was used to evaluate the predictive properties of the models. Hierarchical cluster
192 analysis (HCA), applying m-files in MATLAB, was performed on the $\log k$ values, to visualize the
193 (dis)similarities between the nine tested stationary phases. Scatter plots of the predicted versus the

194 experimental log K_p values were drawn with Graphpad Prism version 9.1.2 (GraphPad Software, San
195 Diego, CA, USA).

196 To reduce the complexity of the obtained stepwise MLR models with E-Dragon descriptors
197 different methods were implemented. First, the RMSECV versus model-complexity (i.e. number of
198 descriptors in the model) curves were looked at to evaluate whether the RMSECV values improved
199 considerably with the addition of each descriptor. This was assessed by calculating Δ RMSECV, as
200 $(\text{RMSECV}_{A-1} - \text{RMSECV}_A)/\text{RMSECV}_{A-1}$, with A the model complexity, for each subsequent pair.
201 When Δ RMSECV was larger than or equal to 0.02, the addition of an extra descriptor substantially
202 improved the model [47]. The RMSECV values can be estimated either by leave-one-out (LOO-CV),
203 or a k-fold CV. Additionally, simplified models may also be obtained by determining a maximal
204 value, $\text{RMSECV}_{\text{Crit}}$, which does not differ significantly from the minimal RMSECV, $\text{RMSECV}_{\text{Min}}$,
205 [48,49]:

$$206 \quad \text{RMSECV}_{\text{Crit}}^2 = F_{(\alpha, N, N)} \text{RMSECV}_{\text{Min}}^2 \quad (\text{Eq. 2})$$

207 $F_{(\alpha, N, N)}$ is at significance level $\alpha = 0.05$ and with N, N degrees of freedom (N being the number of
208 compounds in the training set).

209 **3. Results and discussion**

210 *3.1. Chromatographic measurements*

211 The set of 58 pharmaceutical and cosmetic compounds was analyzed on nine stationary phases. In a
212 first step, the methanol fraction in the mobile phase (calculated with Eq. 1) was determined using a
213 generic gradient and a smaller test set. For the Cholesterol, cyanopropyl (CN) and pentafluorophenyl
214 (PFP) columns, a CO_2/MeOH , 95/5 v/v mobile phase was selected. For the other stationary phases a
215 higher fraction of MeOH was preferred: CO_2/MeOH , 90/10 v/v. These mobile phases were applied to
216 screen the entire test set in isocratic mode. An overview of the obtained retention factors on each
217 column can be consulted in **Table S1** of the Supplementary material.

218 Hierarchical cluster analysis (HCA) was performed to visualize the dissimilarities between the
219 stationary-phase types. The weighted pair group method using arithmetic averages (WPGMA)

220 clustering was applied to link the columns using their log k values. The dissimilarity between the
221 stationary phases was expressed as $1-|r|$, with r the correlation coefficient. Only the compounds that
222 showed a result on all nine columns, i.e. 51 compounds, could be included in this analysis. The
223 resulting dendrogram is shown in **Fig. 1**. Three main clusters can be observed. In a first, the silica and
224 BEH columns show great similarity, as they are clustered very low in the dendrogram. Both stationary
225 phases consist of bare silica, resulting in similar retention profiles. Furthermore, these two columns are
226 clustered with the CN and diol columns, which contain polar groups on their silica surface. A second
227 cluster is composed of two stationary phases with basic properties, containing a pyridine (2-EP) and
228 amino (NH₂) group. These two columns are slightly higher clustered with the more non-polar
229 Cholester column. In the third cluster, containing the PFP and phenyl columns, the similarity can again
230 be attributed to the column chemistries: both columns contain aromatic groups on their silica base.
231 This third cluster is linked relatively high to the first two, showing more dissimilarities in the retention
232 properties. When comparing the dendrogram with previous stationary-phase classifications [32,50], a
233 large resemblance is noticed for the two main clusters, i.e. a distinction can be made between the polar
234 (the two sub-clusters on the left side of **Fig. 1**), and the non-polar and aromatic stationary phases
235 (represented by the PFP and phenyl columns). These previous studies situated the Cholester column in
236 the latter main cluster, unlike the present study. However, in the polar cluster, the Cholester column is
237 the most dissimilar.

238 Next, the correlation between the retention factors (log k) and the skin permeability (log K_p) was
239 assessed. The equations and corresponding statistical parameters for the linear regressions (log $K_p =$
240 $a \log k + b$) are shown in **Table 3**. An inversely proportional relationship between the log k and log K_p
241 values can be noticed. This observation means that compounds with higher skin permeability values,
242 show lower retention and thus less affinity for the more polar (or intermediately polar) stationary
243 phases applied in this study. Furthermore, for the Cholester, 2-EP and NH₂ columns a low correlation
244 with the skin permeability (low r^2 values) was observed. These observations confirm the dendrogram
245 in **Fig. 1**, in which these three column types are part of the same cluster. Thus, there are similarities in
246 their retention profiles, which however showed less correlation with the skin permeation of these

247 compounds. On the other hand, the CN column provided the best correlation with the log K_p values,
248 followed by the BEH, phenyl and diol columns. Even though the silica and BEH columns showed high
249 similarities in their retention profiles, a slightly better correlation with the skin permeability was
250 noticed for the BEH column. While some stationary phases showed promising results, the calibration
251 and prediction errors (RMSEC and RMSECV, respectively) are quite high. Therefore, theoretical
252 descriptors were added to the models to improve the modelling of the skin permeability.

253 3.2. MLR modelling with Vega ZZ descriptors

254 First, Vega ZZ descriptors were applied to enhance the skin permeability models containing the log k
255 values. Multiple linear regression models were set up containing from one to seven descriptors for
256 every stationary phase. The best of these models can be consulted in **Tables S2 to S10** in the
257 Supplementary material. When adding more descriptors to the model, a better fit was noticed (lower
258 RMSEC), together with an improvement of its predictive qualities (decreasing RMSECV). However,
259 at a certain complexity, overfitting of the model occurs, resulting in worse predictive properties
260 (higher RMSECV). The best number of descriptors is thus selected as a compromise between a good
261 fit (RMSEC) and the predictive capacities (RMSECV) of the model.

262 An overview of the best MLR models with the chromatographic descriptor from each stationary
263 phase and Vega ZZ descriptors is presented in **Table 4**. It can be noticed that all models include the
264 Virtual log P as a descriptor. Furthermore, the number of atoms (*Atoms*) is selected in seven out of the
265 nine best models. In correspondence with the results from section 3.1., the models with the Cholesterol,
266 2-EP and NH_2 descriptors were of a slightly lower quality (Eqs. 3, 5 and 8 in **Table 4**, respectively).
267 Furthermore, the best models for these columns were more complex (including five to six descriptors)
268 than the models built with the other chromatographic descriptors. On the other hand, in accordance
269 with the correlation between the retention factors log k and the log K_p values, the overall best model
270 was obtained with the CN descriptor (Eq. 6 in **Table 4**), containing only two other descriptors, the
271 Virtual log P and the number of atoms (*Atoms*), besides log k_{CN} . This simple model shows large
272 similarity to the model of Potts and Guy [51], which used the molecular weight and log P to predict
273 skin permeability coefficients. Considering the high correlation between the molecular weight and

274 number of atoms ($r = 0.95$ with the current test set), these models are similar. The predicted $\log K_p$
275 values of this model are shown as a function of the experimental in **Fig. 2A**. Another descriptor that
276 also performed well was from the diol column, when combined with three Vega ZZ descriptors
277 (Virtual $\log P$, number of atoms and Broto's Lipole) (Eq. 9 in **Table 4**).

278 The MLR (Vega ZZ/CN) model (Eq. 6) was compared to the best models obtained in previous
279 studies with the same test set. The actual model showed an improvement compared to the best MLR
280 model containing only Vega ZZ descriptors, i.e. the MLR (Vega ZZ) model (four descriptors, RMSEC
281 = 0.690 or 25.7%, RMSECV = 0.752 or 28.0% and $r^2 = 0.69$) [34], indicating the added value of the
282 current chromatographic descriptor. Moreover, further improvement is noticed relative to the best
283 models containing a chromatographic descriptor, from two previous studies, i.e. to the MLR (Vega
284 ZZ/MLC on a monolithic column) model (four descriptors, RMSEC = 0.670 or 25.0%, RMSECV =
285 0.734 or 27.4% and $r^2 = 0.72$) [35] and to the MLR (Vega ZZ/IAM) model (four descriptors, RMSEC
286 = 0.636 or 23.7%, RMSECV = 0.702 or 26.1%, $r^2 = 0.74$) [36].

287 *3.3. Stepwise MLR modelling with E-Dragon descriptors*

288 The E-Dragon descriptors were used as a second set of descriptors to model the skin permeability,
289 together with the chromatographic descriptors from each tested stationary phase, using a stepwise
290 MLR approach. An overview of the models that selected a $\log k$ is provided in **Table 5**. The stationary
291 phases for which the chromatographic descriptor was not selected by the stepwise approach (silica,
292 PFP and Cholesterol column) were not included in this table. The number of selected descriptors ranged
293 from 9 to 19, showing higher complexity in comparison to the models built with the Vega ZZ
294 descriptors. This can also be attributed to the size of the descriptor sets (408 E-Dragon vs 22 Vega ZZ
295 descriptors).

296 The best model was obtained with the results from the phenyl column (Eq. 16), showing very
297 good parameters for its fit and predictive properties. The plot of the predicted versus the experimental
298 $\log K_p$ values for this model is shown in **Fig. 2B**. It can be observed that the regression line through
299 the data points and the bisector almost coincide. Furthermore, all data points are situated close to the

300 regression line. However, with 19 descriptors, this model is also the most complex. The MLR (E-
301 Dragon/CN) model provided a good alternative, with a total of 12 descriptors (Eq. 13). Models which
302 performed less good were those composed with the results from the 2-EP and NH₂ columns (Eqs. 12
303 and 14, respectively). Both models include nine descriptors, which often are the same (seven out of the
304 eight descriptors selected, besides log *k*, are identical). However, it should be noted that even the less
305 good performing models with this stepwise approach still show better statistical parameters than the
306 MLR models built with the Vega ZZ descriptors.

307 The current best stepwise MLR model, i.e. MLR (E-Dragon/Phenyl) performed also better than
308 the MLR (E-Dragon) model (ten descriptors, RMSEC = 0.378 or 14.1%, RMSECV = 0.452 or 16.8%
309 and $r^2 = 0.91$) from a previous study [34]. A similar enhancement of the performance parameters was
310 noticed relative to the best MLR (E-Dragon/MLC) model (ten descriptors, RMSEC = 0.329 or 12.4%,
311 RMSECV = 0.399 or 15.0% and $r^2 = 0.93$) [35]. On the other hand, similar results were obtained as
312 for the best MLR (E-Dragon/UHPLC) model (16 descriptors, RMSEC = 0.177 or 6.6%, RMSECV =
313 0.245 or 9.2% and $r^2 = 0.98$) [36].

314 *3.4. Reducing the complexity of the MLR models*

315 The stepwise MLR models built with E-Dragon descriptors are rather extensive, containing from 9 to
316 19 descriptors, and risk to be overfitting. This should be avoided when using the models in ‘real-life’
317 circumstances, e.g. for the prediction of the skin permeability of potential drug candidates. It is
318 essential that the models also predict well for new compounds. Therefore, it was examined whether
319 the MLR models could be simplified, while maintaining their performance quality. A first approach
320 consisted of evaluating the RMSECV vs model complexity by assessing whether $\Delta\text{RMSECV} \geq 0.02$
321 for each descriptor added to a simpler model. This may be done with both the results from LOO-CV or
322 k-fold CV, where the latter may provide a better indication of a possible overfitting of the models [52].
323 A second approach is based on calculating an RMSECV_{Crit} value (Eq. 2). Since the aim was to obtain
324 simpler models, which still contain a chromatographic descriptor, the number of descriptors could be
325 barely decreased for the models containing the retention on the 2-EP and NH₂-bonded phases. In both

326 cases, the chromatographic descriptor was selected as the eighth of nine. Therefore, these simplified
327 models were not discussed.

328 The MLR (E-Dragon/CN) model (Eq. 13 in **Table 5**) contains 12 descriptors. When examining
329 Δ RMSECV, both with LOO-CV and k-fold CV, the addition of every descriptor to the model was
330 justified. However, considering the RMSECV_{crit} value from LOO-CV, the model could be reduced to
331 nine descriptors:

$$\begin{aligned} \log K_p = & -2.08 - 1.23 \log k_{CN} - 0.49 nHAcc + 0.12 R_{ww} - 1.36 L3m - 0.51 ALOGPS_{logS} - \\ & 0.13 H-051 - 0.35 IDDE + 0.43 Mor07m + 0.96 Mor17p \end{aligned} \quad (\text{Eq. 18})$$

334 with RMSEC = 0.282 (10.7%), RMSECV = 0.353 (13.4%) and $r^2 = 0.95$ ($n = 53$).

335 This simplified model still displays very good performance parameters compared to the initial model.
336 Furthermore, it performs better than the equivalent MLR (Vega ZZ/CN) model (Eq. 6 in **Table 4**).

337 Next, the MLR (E-Dragon/Diol) model (ten descriptors, see Eq. 15 in **Table 5**) was evaluated.
338 The Δ RMSECV values obtained with LOO-CV, indicated a simplification to two descriptors. Since
339 this drastically and dramatically impacted the performance parameters, the results are not shown. In
340 contrast, the same approach based on k-fold CV showed that the addition of the seventh descriptor did
341 not sufficiently improve the RMSECV values, thus leading to a model with six descriptors:

$$\begin{aligned} \log K_p = & -1.48 + 0.30 C-025 - 0.95 \log k_{Diol} + 0.30 ALOGPS_{logP} - 0.97 EEig01r + 0.89 Jhetp \\ & + 52.19 R8v+ \end{aligned} \quad (\text{Eq. 19})$$

344 with RMSEC = 0.390 (14.6%), RMSECV = 0.449 (16.8%) and $r^2 = 0.90$ ($n = 56$).

345 The same reduction in model complexity was made considering the RMSECV_{crit} value. The
346 performance parameters of the simplified model were similar to those of the original, and still better
347 than those of the corresponding MLR (Vega ZZ/Diol) model (Eq. 9 in **Table 4**).

348 The most complex, but best performing model was the MLR (E-Dragon/Phenyl) model (Eq. 16 in
349 **Table 5**). However, with a total of 19 descriptors, the risk of overfitting is high. The experimental
350 descriptor was selected as sixth, thus requiring the simplified model to contain at least this number of

351 descriptors. Considering Δ RMSECV with LOO-CV, the model could be reduced to 15 descriptors,
352 while applying k-fold CV showed that the addition of a 10th descriptor did not further improve the
353 RMSECV value. The model with nine descriptors is:

$$\begin{aligned} \log K_p = & -3.39 - 0.25 \text{ RDF020e} + 0.44 \text{ C-025} - 0.00048 \text{ SRW09} - 0.013 \text{ D/Dr06} + 11.39 \text{ JGI4} \\ & - 1.39 \log k_{\text{phenyl}} - 0.83 \text{ ALOGPS_logS} + 0.22 \text{ H-047} - 0.92 \text{ nBnz} \end{aligned} \quad (\text{Eq. 20})$$

356 with RMSEC = 0.382 (14.2%), RMSECV = 0.482 (18.0%) and $r^2 = 0.91$ ($n = 58$).

357 This distinct reduction in number of descriptors leads to a decreased quality of the performance
358 parameters. However, they were still similar to those of the other simplified models. Furthermore, this
359 simpler model performed better than the corresponding MLR (Vega ZZ/Phenyl) model (Eq. 10 in
360 **Table 4**). When applying the RMSECV_{crit} value, only a reduction to 17 descriptors can be made.
361 However, because of the limited decrease in complexity, this model was not explored further.

362 The MLR (E-Dragon/BEH) model contained nine descriptors (Eq. 17 in **Table 5**). The
363 Δ RMSECV showed the added value of each subsequent descriptor in the model, both in case of LOO-
364 CV and k-fold CV. However, the number of descriptors could be decreased considering the
365 RMSECV_{crit} value (with LOO-CV), leading to a model with five descriptors:

$$\log K_p = -2.83 + 0.54 \text{ ALOGP} - 0.84 \log k_{\text{BEH}} - 0.25 \text{ nCs} - 2.19 \text{ E2s} + 1.17 \text{ MATS2p} \quad (\text{Eq. 21})$$

367 with RMSEC = 0.415 (15.8%), RMSECV = 0.476 (18.1%) and $r^2 = 0.89$ ($n = 54$).

368 Once more, the slight decrease in the quality of the performance parameters still resulted in a better
369 model than the corresponding MLR (Vega ZZ/BEH) model (Eq. 11 in **Table 4**).

370 It can be concluded that it is possible to obtain simpler versions of the MLR models to predict
371 skin permeability with acceptable quality. The best simplified model was obtained with the results on
372 the CN column (Eq. 18). **Fig. 2C** shows the predicted versus the experimental $\log K_p$ values for this
373 model, in which a strong resemblance is seen between the bisector and the regression line through the
374 data points. Although the MLR (E-Dragon/Phenyl) model initially was the best, it is now observed
375 that the simplified MLR (E-Dragon/CN) version performed better than the simplified MLR (E-

376 Dragon/Phenyl) model. These latter two models can be directly compared because they both contain
377 the same number of descriptors.

378 Each simplified model still was better than the corresponding model including Vega ZZ
379 descriptors. However, it could be noticed that these Vega ZZ models still contained less descriptors
380 than the simplified E-Dragon models. This observation could be attributed to the limited number of
381 descriptors in the Vega ZZ set compared to the E-Dragon one (22 vs 408 descriptors, respectively),
382 providing less potential to obtain models with satisfactory quality.

383 Compared to the best stepwise MLR models obtained in previous studies [34–36], the simplified
384 MLR (E-Dragon/CN) model (Eq. 18) performed better than the MLR (E-Dragon) and MLR (E-
385 Dragon/MLC) models (parameters shown in section 3.3.). However, its performance parameters did
386 not surpass those of the MLR (E-Dragon/UHPLC) model (parameters shown in section 3.3), nor those
387 of the MLR (E-Dragon/IAM) (14 descriptors, RMSEC = 0.225 or 8.4%, RMSECV = 0.298 or 11.1%,
388 and $r^2 = 0.97$) and MLR (E-Dragon/Cholester in HPLC) (16 descriptors, RMSEC = 0.232 or 8.6%,
389 RMSECV = 0.304 or 11.3% and $r^2 = 0.97$) models. Nevertheless, similar performance parameters
390 were obtained to the simplified versions of the latter three models [36].

391 3.5. PLS modelling

392 As an alternative to the MLR modelling, PLS modelling was applied to both the Vega ZZ and the E-
393 Dragon descriptor sets, combined with the experimental descriptor from the SFC analyses. The
394 number of latent variables in the model was selected based on the lowest RMSECV value (with LOO-
395 CV). The results for the best PLS models with each stationary phase are shown in **Table 6**. The best
396 PLS model built with Vega ZZ descriptors contained also the results from the CN column. For this
397 model, nine PLS factors were selected. The predicted $\log K_p$ values were plotted against the
398 experimental in **Fig. 2D**. They show more scatter around the regression line for the lower skin
399 permeability values. Furthermore, it should be remarked that when using other chromatographic
400 descriptors, less latent variables were selected, ranging from five to seven PLS factors. The PLS
401 (Vega ZZ/Cholester) and PLS (Vega ZZ/NH₂) models fitted least good, while the PLS

402 (Vega ZZ/BEH) model showed the least good predictive qualities (RMSECV value). Besides the PLS
403 models obtained with the CN and diol descriptors (the most complex models), the other models
404 presented a lower performance quality.

405 The best PLS and MLR (Eq. 6 in **Table 4**) models with Vega ZZ descriptors were both obtained
406 with the descriptor from the CN column. The PLS model performs slightly less good, especially when
407 looking at the RMSECV value. In comparison to the corresponding best PLS (Vega ZZ) model (five
408 PLS factors, RMSEC = 0.757 or 28.2%, RMSECV = 0.807 or 30.0% and $r^2 = 0.63$) [34], the PLS
409 (Vega ZZ/CN) model showed better performance parameters. The same observation is made when
410 comparing this model to the best PLS (Vega ZZ/MLC) model (monolithic column, seven latent
411 variables, RMSEC = 0.683 or 25.6%, RMSECV = 0.797 or 29.9%, $r^2 = 0.70$) [35] on the one hand,
412 and the PLS (Vega ZZ/IAM) model (six latent variables, RMSEC = 0.674 or 25.1%, RMSECV =
413 0.763 or 28.4% and $r^2 = 0.71$) [36] on the other.

414 The same approach applied on the E-Dragon descriptors resulted in a number of PLS factors
415 varying between six and nine (**Table 6**). Overall, for most stationary phases an improved model fit
416 (lower RMSEC and higher r^2) is noticed compared to the PLS models with the Vega ZZ descriptors.
417 However, the increased RMSECV values of the E-Dragon PLS models mean that their predictive
418 capacities were less good. Again, the best PLS model is associated with the most latent variables, i.e.
419 the PLS (E-Dragon/Silica) model (nine PLS factors), for which a clearly better fit is noticed than for
420 the PLS (Vega ZZ/CN) model. The model risks to be overfitting given its complexity and much less
421 good predictive properties (high RMSECV relative to RMSEC). In **Fig. 2E** it is again seen that the
422 most challenging compounds to model are those with lower $\log K_p$ values. The RMSECV value of the
423 PLS (Vega ZZ/CN) model was better than that of this model. Moreover, the best PLS model does not
424 surpass the parameters of the MLR (E-Dragon/Phenyl) model (Eq. 16 in **Table 5**), nor the best
425 simplified MLR (E-Dragon/CN) model (Eq. 18). A similarly performing PLS model with E-Dragon
426 descriptors was obtained for the CN column, selecting eight PLS factors. On the other hand, the other
427 PLS models showed a comparable less good fit, while the worst RMSECV values were obtained for
428 the PFP and BEH columns (all selecting six PLS factors).

429 Compared to the best PLS (E-Dragon) model (six PLS factors, RMSEC = 0.674 or 25.1%,
430 RMSECV = 0.860 or 32.0% and $r^2 = 0.72$) [34], the PLS (E-Dragon/Silica) model showed an
431 improved result. However, the performance parameters did not surpass those of the PLS (E-
432 Dragon/MLC) model (particle-based column with nine PLS factors, RMSEC = 0.421 or 15.8%,
433 RMSECV = 0.730 or 27.4%, $r^2 = 0.89$) [35], nor of the PLS (E-Dragon/Cholesterol in HPLC) model
434 (ten PLS factors, RMSEC = 0.424 or 15.7%, RMSECV = 0.854 or 31.7% and $r^2 = 0.89$) [36].

435 **4. Conclusions**

436 In this paper, SFC was introduced as a new alternative to the previously tested HPLC and UHPLC
437 techniques to model skin permeability. In this context, nine stationary-phase types were screened in
438 SFC using a test set of 58 pharmaceutical and cosmetic compounds. The best correlation between the
439 retention factors ($\log k$) and the skin permeability coefficient ($\log K_p$) was obtained with the CN
440 column. The retention on this column also provided one of the best models with each modeling
441 approach. The $\log k_{CN}$ in combination with Vega ZZ descriptors Virtual $\log P$ and number of atoms
442 provided the best MLR model. In this way, a simple model was obtained, which showed resemblance
443 to the skin permeability model introduced by Potts and Guy [51]. The overall best model in this study
444 was obtained with the stepwise MLR approach and contains 18 E-Dragon descriptors and $\log k_{phenyl}$.
445 Both for the fit and the predictions, this model performed very well with relative errors below 10%.
446 The complexity of most MLR models built with E-Dragon descriptors could be reduced without
447 dramatically impacting the quality of their performance. Among the latter, the MLR (E-Dragon/CN)
448 model, including nine descriptors, provided the best result. For a given descriptor set, the MLR models
449 were better than the corresponding PLS models.

450 When comparing the best models with those from previous studies [34–36], it can be concluded
451 that the current MLR models performed better. The PLS model built with the Vega ZZ descriptors
452 also did. The best simplified MLR model was not better than the best MLR (E-Dragon/UHPLC), MLR
453 (E-Dragon/IAM) and MLR (E-Dragon/Cholesterol in HPLC) models. However, its performance
454 parameters were similar to the simplified versions of the latter three models. Furthermore, the best
455 PLS (E-Dragon/Silica) model did not surpass the performance parameters of the previously obtained

456 best PLS models, except for the PLS (E-Dragon) model. The overall best model was the stepwise
457 MLR (E-Dragon/Phenyl) model.


458 It can be concluded that several stationary phases in SFC provide a suitable alternative for the
459 currently used RPLC methods to predict skin permeability. Furthermore, only 5 or 10% methanol was
460 needed as organic modifier in the mobile phase, attributing to the 'green' character of the proposed
461 methods. However, it should be noted that the currently obtained models should be further validated,
462 preferably with an extended external test set.

463 **Acknowledgments**

464 Y.G. is funded by a Ph.D. fellowship of the Research Foundation Flanders (FWO) [grant 11D3518N].
465 The authors thank R. Verellen for technical assistance.


466 **Conflict of Interest**

467 The authors declare that they have no conflict of interest.



469

470 **Fig. 1.** Dendrogram based on WPGMA clustering, showing the (dis)similarities between the nine
 471 tested stationary phases (using the log *k* values for 51 compounds).



472

473 **Fig. 2.** The predicted versus the experimental $\log K_p$ values, together with the regression line (solid
 474 line) and bisector ($y = x$, dashed line), for A) the MLR (Vega ZZ/CN) model (Eq. 6); B) the stepwise
 475 MLR (E-Dragon/Phenyl) model (Eq. 16); C) the simplified stepwise MLR (E-Dragon/CN) model
 476 (Eq. 18); D) the PLS (Vega ZZ/CN) model; and E) the PLS (E-Dragon/Silica) model.

478 **Table 1.** An overview of the compounds in the test set.

Compound	log P^a	log D^b	log K_p^c	Company
17 α -hydroxyprogesterone	1.84	3.40	-3.22	Sigma-Aldrich
2,4,6-Trichlorophenol	3.94	3.36	-1.23	Sigma-Aldrich
2,4-Dichlorophenol	3.18	2.87	-1.22	Sigma-Aldrich
2-Amino-4-nitrophenol	1.39	0.78	-3.18	Sigma-Aldrich
2-Nitro-p-phenylenediamine	0.78	0.90	-3.30	Sigma-Aldrich
4-Amino-2-nitrophenol	1.22	0.78	-2.55	Sigma-Aldrich
Acetylsalicylic acid	1.10	-0.84	-2.14 [39]	Sigma-Aldrich
Aminopyrine	1.57	1.14	-2.99	Sigma-Aldrich
Amylobarbitol	1.97	1.89	-2.64	Bios
Antipyrine	1.26	1.22	-4.18	Unknown origin
Atropine	2.14	-1.78	-5.07	Sigma-Aldrich
Barbital	0.95	0.71	-3.96	Bios Coutelier
Benzoic acid	1.24	0.19	-1.52	Merck
Benzyl alcohol	1.34	1.21	-2.22	Sigma-Aldrich
Caffeine	-0.25	-0.55	-2.80	Fluka
Chloroxylenol	3.06	3.30	-1.23	Sigma-Aldrich
Chlorpheniramine (maleate)	3.86	0.21	-2.66	Sigma-Aldrich
Cortexolone	0.97	2.58	-4.12	Sigma-Aldrich
Cortexone	1.92	3.33	-3.35	Sigma-Aldrich
Corticosterone	0.82	2.02	-3.19	Sigma-Aldrich
Cortisone	-0.12	1.66	-5.00	Sigma-Aldrich
Diclofenac	4.45	2.75	-1.74	Sigma-Aldrich
Ephedrine.HCl	1.73	-1.86	-2.22	Sigma-Aldrich
Estriol	2.30	2.67	-4.40	Unknown origin
Estrone	3.18	4.31	-2.44	Diosynth
Ethyl nicotinate	1.35	1.11	-2.20	Sigma-Aldrich
Flurbiprofen	3.88	2.83	-0.34	Sigma-Aldrich
Haloperidol	3.75	1.16	-4.04 [40]	Unknown origin
Hydrocortisone	0.01	1.28	-5.52	Certa
Ibuprofen	3.20	3.11	-0.24	Sigma-Aldrich
Indomethacin	4.04	1.82	-1.30	Sigma-Aldrich
Ketoprofen	2.23	1.99	-1.23	Sigma-Aldrich
Lidocaine	3.01	0.61	-1.70 [41]	Sigma-Aldrich
m-Cresol	2.09	2.18	-1.82	Sigma-Aldrich
Methyl nicotinate	0.93	0.76	-2.49	Sigma-Aldrich
Methyl-4-hydroxybenzoate	1.36	1.67	-2.04	Fluka
m-Nitrophenol	2.21	1.61	-2.25	Sigma-Aldrich
Naproxen	3.23	1.66	-1.42	Sigma-Aldrich
o-Chlorophenol	2.40	2.27	-1.48	Sigma-Aldrich
o-Cresol	2.07	2.18	-1.80	Sigma-Aldrich
Paracetamol	1.07	0.91	-3.35	Sigma-Aldrich
p-Cresol	2.16	2.18	-0.92	Sigma-Aldrich

Phenobarbitone	1.49	1.40	-3.35	Unknown origin
Phenol	1.59	1.67	-1.71	Merck
Piroxicam	1.59	0.03	-2.47	Sigma-Aldrich
p-Nitrophenol	2.17	1.60	-2.25	Sigma-Aldrich
p-Phenylenediamine	0.23	-0.67	-3.62	Sigma-Aldrich
Prednisolone	-0.45	1.27	-4.35	Sigma-Aldrich
Progesterone	2.85	4.15	-2.82	Sigma-Aldrich
Resorcinol	1.18	1.37	-3.62	Merck
Salicylic acid	0.96	-0.67	-2.20	Sigma-Aldrich
Testosterone	2.48	3.37	-3.40	Sigma-Aldrich
Thiourea	-0.65	-0.47	-4.02 [42]	Merck
Thymol	3.23	3.43	-1.28	Sigma-Aldrich
Triamcinolone	-1.13	0.24	-5.40	Sigma-Aldrich
Triamcinolone acetonide	1.40	1.94	-4.69	Sigma-Aldrich
β -estradiol	3.37	3.75	-2.37	Unknown origin
β -naphthol	2.61	2.66	-1.55	Merck

479 ^a Virtual log P , calculated using Vega ZZ

480 ^b pH dependent hydrophobicity, log D , calculated using Chemicalize at pH 5.5

481 ^c Skin permeability coefficient log K_p , taken from [38], unless a different source was indicated

482 **Table 2.** The stationary phases selected for this study and their specifications.

Stationary phase	Denotation	Column dimensions	Manufacturer	Description
Cosmosil Cholester	Cholester	150 mm x 4.6 mm i.d., 5 μ m	Nacalai Tesque	Cholesteryl groups bound to silica
Luna Silica	Silica	100 mm x 4.6 mm i.d., 3 μ m	Phenomenex	Bare silica
Viridis Silica 2-EP	2-EP	100 mm x 4.6 mm i.d., 5 μ m	Waters	2-ethylpyridine groups bound to silica
Luna CN	CN	100 mm x 4.6 mm i.d., 3 μ m	Phenomenex	Cyanopropyl groups bound to silica
Luna PFP	PFP	100 mm x 4.6 mm i.d., 3 μ m	Phenomenex	Pentafluorophenylpropyl groups bound to silica
Luna NH ₂	NH ₂	100 mm x 4.6 mm i.d., 3 μ m	Phenomenex	Aminopropyl groups bound to silica
Luna HILIC	Diol	100 mm x 4.6 mm i.d., 3 μ m	Phenomenex	Cross-linked diol groups covering silica
Synergi Polar RP	Phenyl	100 mm x 4.6 mm i.d., 4 μ m	Phenomenex	Phenyl-oxypropyl groups bound to silica
Acquity UPC ² BEH	BEH	100 mm x 3 mm i.d., 1.7 μ m	Waters	Ethylene bridged hybrid (BEH) silica

483

484 **Table 3.** Results of the modelling of the skin permeability coefficient $\log K_p$ as a function of the retention factors $\log k$ from the different stationary phases
 485 ($\log K_p = a \log k + b$).

Stationary phase	<i>n</i>	RMSEC	RMSECV	<i>r</i> ²	<i>a</i>	<i>b</i>
Cholester	58	1.211 (45.1%)	1.251 (46.6%)	0.05	-0.68	-2.57
Silica	54	1.029 (39.5%)	1.094 (41.9%)	0.29	-1.34	-2.27
2-EP	58	1.218 (45.3%)	1.254 (46.7%)	0.04	-0.61	-2.42
CN	53	0.851 (32.4%)	0.903 (34.4%)	0.52	-1.65	-2.08
PFP	54	1.016 (38.6%)	1.066 (40.5%)	0.33	-1.83	-3.10
NH ₂	57	1.223 (45.4%)	1.262 (46.8%)	0.05	-0.47	-2.37
Diol	56	0.997 (37.2%)	1.037 (38.7%)	0.37	-1.39	-2.31
Phenyl	58	0.982 (36.6%)	1.025 (38.1%)	0.38	-1.98	-2.44
BEH	54	0.975 (37.0%)	1.025 (38.9%)	0.38	-1.73	-2.78

486 *n* is the number of compounds included in the modelling, RMSEC and RMSECV the root mean squared error of calibration and of cross validation (together
 487 with their relative values), respectively, *r*² the determination coefficient, *a* the slope and *b* the intercept of the equation.

488 **Table 4.** The best MLR models built with Vega ZZ descriptors and the chromatographic descriptors from each stationary phase.

Column	<i>n</i>	RMSEC	RMSECV	<i>r</i> ²	Equation
Cholester	58	0.665 (24.8%)	0.737 (27.4%)	0.71	$\log K_p = -3.27 - 0.78 \log k_{Chol} - 0.038 \textit{Atoms} + 0.60 \textit{Virtual log P} + 0.23 \textit{Lipole (Broto)} + 0.12 \textit{HbAcc}$ (Eq. 3)
Silica	54	0.585 (22.4%)	0.649 (24.9%)	0.77	$\log K_p = -2.42 + 0.55 \textit{Virtual log P} - 0.0034 \textit{Melting point} - 0.48 \log k_{Silica} - 0.021 \textit{Atoms}$ (Eq. 4)
2-EP	58	0.663 (24.7%)	0.731 (27.2%)	0.72	$\log K_p = -2.86 - 0.75 \log k_{2-EP} - 0.048 \textit{Atoms} + 0.53 \textit{Virtual log P} + 0.28 \textit{Lipole (Broto)} + 0.17 \textit{HbAcc}$ (Eq. 5)
CN	53	0.537 (20.5%)	0.580 (22.1%)	0.81	$\log K_p = -2.58 - 0.88 \log k_{CN} + 0.53 \textit{Virtual log P} - 0.024 \textit{Atoms}$ (Eq. 6)
PFP	54	0.615 (23.4%)	0.695 (26.4%)	0.75	$\log K_p = -2.62 + 0.51 \textit{Virtual log P} - 0.76 \log k_{PFP} - 0.027 \textit{Atoms} - 0.24 \textit{HbDon}$ (Eq. 7)
NH ₂	57	0.674 (25.0%)	0.768 (28.5%)	0.71	$\log K_p = -1.44 + 0.24 \log k_{NH_2} - 0.0043 \textit{Melting point} + 0.63 \textit{Virtual log P} + 0.011 \textit{PSA} - 0.36 \textit{HbDon} - 0.70 \textit{Gyration radius}$ (Eq. 8)
Diol	56	0.555 (20.7%)	0.607 (22.7%)	0.81	$\log K_p = -2.75 + 0.49 \textit{Virtual log P} - 0.93 \log k_{Diol} - 0.029 \textit{Atoms} + 0.15 \textit{Lipole (Broto)}$ (Eq. 9)
Phenyl	58	0.621 (23.1%)	0.672 (25.0%)	0.75	$\log K_p = -2.92 + 0.49 \textit{Virtual log P} - 1.76 \log k_{Phenyl} - 0.0088 \textit{PSA}$ (Eq. 10)
BEH	54	0.607 (23.0%)	0.662 (25.1%)	0.76	$\log K_p = -2.88 + 0.56 \textit{Virtual log P} - 0.89 \log k_{BEH} - 0.029 \textit{Atoms}$ (Eq. 11)

489 *HbAcc* = number of hydrogen bond acceptors, *HbDon* = number of hydrogen bond donors, *PSA* = polar surface area.

490 *n* is the number of compounds included in the modelling, RMSEC and RMSEV the root mean squared error of calibration and of cross validation (together

491 with their relative values), respectively, and *r*² the determination coefficient.

492 **Table 5.** The best stepwise MLR models including E-Dragon and chromatographic descriptors from the various stationary phases.

Column	<i>n</i>	RMSEC	RMSECV	<i>r</i> ²	Equation
2-EP	58	0.389 (14.5%)	0.470 (17.5%)	0.90	$\log K_p = -6.33 - 0.32 \text{RDF020e} + 0.81 \text{C-025} + 0.24 \text{RDF055p} - 0.00098 \text{SRW09} - 1.17 \text{Glu} - 0.0072 \text{D/Dr06} + 5.87 \text{JGI4} - 0.39 \log k_{2-EP} + 1.27 \text{BEHmI}$ (Eq. 12)
CN	53	0.223 (8.5%)	0.282 (10.7%)	0.97	$\log K_p = -1.52 - 1.14 \log k_{CN} - 0.57 \text{nHAcc} + 0.12 \text{Rww} - 1.51 \text{L3m} - 0.53 \text{ALOGPS_logS} - 0.16 \text{H-051} - 0.39 \text{IDDE} + 0.55 \text{Mor07m} + 1.79 \text{Mor17p} - 0.71 \text{Mor15u} + 0.058 \text{RDF065m} - 0.56 \text{Glu}$ (Eq. 13)
NH ₂	57	0.388 (14.4%)	0.457 (17.0%)	0.90	$\log K_p = -7.62 - 0.32 \text{RDF020e} + 0.80 \text{C-025} + 0.25 \text{RDF055p} - 0.0010 \text{SRW09} - 0.90 \text{Glu} - 0.0075 \text{D/Dr06} + 1.65 \text{BEHmI} - 0.34 \log k_{\text{NH}_2} - 0.48 \text{MATS4e}$ (Eq. 14)
Diol	56	0.307 (11.5%)	0.368 (13.7%)	0.94	$\log K_p = -1.22 + 0.46 \text{C-025} - 1.02 \log k_{\text{Diol}} + 0.19 \text{ALOGPS_logP} - 0.82 \text{EEig01r} + 0.61 \text{Jhetp} + 63.29 \text{R8v+} + 0.055 \text{G(N..N)} + 9.55 \text{JGI4} - 1.38 \text{HATS2u} + 0.48 \text{Mor13m}$ (Eq. 15)
Phenyl	58	0.167 (6.2%)	0.238 (8.9%)	0.98	$\log K_p = -3.82 - 0.13 \text{RDF020e} + 0.74 \text{C-025} - 0.00059 \text{SRW09} - 0.022 \text{D/Dr06} + 15.48 \text{JGI4} - 1.79 \log k_{\text{phenyl}} - 0.80 \text{ALOGPS_logS} + 0.24 \text{H-047} - 1.07 \text{nBnz} + 0.78 \text{EEig13x} + 23.51 \text{JGI7} - 0.034 \text{G(O..O)} + 0.25 \text{nCconj} - 0.26 \text{Mor09e} + 0.076 \text{RDF090e} - 0.83 \text{Mor20e} + 1.07 \text{MATS1m} + 0.22 \text{S3K} + 0.41 \text{H1m}$ (Eq. 16)
BEH	54	0.313 (11.9%)	0.387 (14.7%)	0.94	$\log K_p = -3.62 + 0.63 \text{ALOGP} - 1.36 \log k_{\text{BEH}} - 0.25 \text{nCs} - 1.12 \text{E2s} + 2.06 \text{MATS2p} - 1.17 \text{L3m} + 0.072 \text{RDF065m} + 0.28 \text{Hy} - 0.46 \text{Mor18u}$ (Eq. 17)

493 *n* is the number of compounds included in the modelling, RMSEC and RMSEV the root mean squared error of calibration and of cross validation (together

494 with their relative values), respectively, and *r*² the determination coefficient.

495 **Table 6.** The performance parameters for the PLS models with the Vega ZZ and the E-Dragon descriptors.

Column	<i>n</i>	Vega ZZ descriptors				E-Dragon descriptors			
		# PLS factors	RMSEC	RMSECV	<i>r</i> ²	# PLS factors	RMSEC	RMSECV	<i>r</i> ²
Cholester	58	5	0.757 (28.2%)	0.805 (30.0%)	0.63	6	0.674 (25.1%)	0.860 (32.0%)	0.72
Silica	54	5	0.705 (27.0%)	0.711 (27.3%)	0.67	9	0.431 (16.5%)	0.769 (29.5%)	0.88
2-EP	58	6	0.710 (26.4%)	0.812 (30.2%)	0.68	6	0.674 (25.1%)	0.860 (32.0%)	0.72
CN	53	9	0.590 (22.5%)	0.674 (25.7%)	0.77	8	0.470 (17.9%)	0.808 (30.8%)	0.85
PFP	54	5	0.727 (27.6%)	0.761 (28.9%)	0.66	6	0.648 (24.6%)	0.941 (35.7%)	0.74
NH ₂	57	5	0.760 (28.2%)	0.798 (29.6%)	0.64	6	0.679 (25.2%)	0.867 (32.2%)	0.72
Diol	56	7	0.643 (24.0%)	0.720 (26.9%)	0.74	6	0.674 (25.2%)	0.877 (32.8%)	0.73
Phenyl	58	5	0.754 (28.1%)	0.791 (29.4%)	0.64	6	0.674 (25.1%)	0.860 (32.0%)	0.72
BEH	54	5	0.724 (27.5%)	0.814 (30.9%)	0.66	6	0.648 (24.6%)	0.941 (35.7%)	0.74

496 *n*: number of compounds included in the modelling, RMSEC and RMSEV: the root mean squared errors of calibration and cross validation (together with
 497 their relative values), respectively, *r*²: the determination coefficient.

498 **References**

- 499 [1] K.A. Walters, M.S. Roberts, The Structure and Function of Skin, in: K.A. Walters (Ed.),
500 Dermatological and Transdermal Formulations, CRC Press, Florida, USA, 2002: pp. 1–39.
- 501 [2] G.P. Moss, D.R. Gullick, S.C. Wilkinson, Predictive Methods in Percutaneous Absorption,
502 Springer Verlag, Heidelberg, Germany, 2015.
- 503 [3] J. Kielhorn, S. Melching-Kollmuß, I. Mangelsdorf, Environmental Health Criteria 235: Dermal
504 Absorption, World Health Organization Press, Geneva, 2006.
505 <https://incem.org/documents/ehc/ehc/ehc235.pdf>.
- 506 [4] R. Neupane, S.H.S. Boddu, J. Renukuntla, R.J. Babu, A.K. Tiwari, Alternatives to biological
507 skin in permeation studies: Current trends and possibilities, *Pharmaceutics*. 12 (2020) 152.
508 <https://doi.org/10.3390/pharmaceutics12020152>.
- 509 [5] J. Buzek, B. Ask, Regulation (EC) No 1223/2009 of the European Parliament and of the
510 Council of 30 November 2009 on cosmetic products, *Off. J. Eur. Union L*. 342 (2009) 59–209.
- 511 [6] G.P. Moss, J.C. Dearden, H. Patel, M.T.D. Cronin, Quantitative structure – permeability
512 relationships (QSPRs) for percutaneous absorption, *Toxicol. in Vitro*. 16 (2002) 299–317.
513 [https://doi.org/10.1016/S0887-2333\(02\)00003-6](https://doi.org/10.1016/S0887-2333(02)00003-6).
- 514 [7] S. Geinoz, R.H. Guy, B. Testa, P.A. Carrupt, Quantitative structure-permeation relationships
515 (QSPeRs) to predict skin permeation: A critical evaluation, *Pharm. Res*. 21 (2004) 83–92.
516 <https://doi.org/10.1023/B:PHAM.0000012155.27488.2b>.
- 517 [8] I. Tsakovska, I. Pajeva, M. al Sharif, P. Alov, E. Fioravanzo, S. Kovarich, A.P. Worth, A.N.
518 Richarz, C. Yang, A. Mostrag-Szlichtyng, M.T.D. Cronin, Quantitative structure-skin
519 permeability relationships, *Toxicology*. 387 (2017) 27–42.
520 <https://doi.org/10.1016/j.tox.2017.06.008>.
- 521 [9] S. Soriano-Meseguer, E. Fuguet, A. Port, M. Rosés, Estimation of skin permeation by liquid
522 chromatography, *ADMET DMPK*. 6 (2018) 140–152. <https://doi.org/10.5599/admet.512>.

- 523 [10] A. Nasal, M. Sznitowska, A. Buciński, R. Kaliszan, Hydrophobicity parameter from high-
524 performance liquid chromatography on an immobilized artificial membrane column and its
525 relationship to bioactivity, *J. Chromatogr. A.* 692 (1995) 83–89. [https://doi.org/10.1016/0021-](https://doi.org/10.1016/0021-9673(94)00689-7)
526 9673(94)00689-7.
- 527 [11] F. Barbato, B. Cappello, A. Miro, M.I. la Rotonda, F. Quaglia, Chromatographic indexes on
528 immobilized artificial membranes for the prediction of transdermal transport of drugs, *II*
529 *Farmaco.* 53 (1998) 655–661. [https://doi.org/10.1016/S0014-827X\(98\)00082-2](https://doi.org/10.1016/S0014-827X(98)00082-2).
- 530 [12] E. Lázaro, C. Ràfols, M.H. Abraham, M. Rosés, Chromatographic estimation of drug
531 disposition properties by means of immobilized artificial membranes (IAM) and C18 columns,
532 *J. Med. Chem.* 49 (2006) 4861–4870. <https://doi.org/10.1021/jm0602108>.
- 533 [13] M. Hidalgo-Rodríguez, S. Soriano-Meseguer, E. Fuguet, C. Ràfols, M. Rosés, Evaluation of
534 the suitability of chromatographic systems to predict human skin permeation of neutral
535 compounds, *Eur. J. Pharm. Sci.* 50 (2013) 557–568. <https://doi.org/10.1016/j.ejps.2013.04.005>.
- 536 [14] A.W. Sobańska, E. Brzezińska, IAM Chromatographic Models of Skin Permeation, *Molecules.*
537 27 (2022) 1893. <https://doi.org/10.3390/molecules27061893>.
- 538 [15] M. Janicka, Correlations between chromatographic parameters and bioactivity predictors of
539 potential herbicides, *J. Chromatogr. Sci.* 52 (2014) 676–684.
540 <https://doi.org/10.1093/chromsci/bmt098>.
- 541 [16] M. Janicka, M. Sztanke, K. Sztanke, Reversed-phase liquid chromatography with
542 octadecylsilyl, immobilized artificial membrane and cholesterol columns in correlation studies
543 with in silico biological descriptors of newly synthesized antiproliferative and analgesic active
544 compounds, *J. Chromatogr. A.* 1318 (2013) 92–101.
545 <https://doi.org/10.1016/j.chroma.2013.09.060>.

- 546 [17] M. Turowski, R. Kaliszan, Keratin immobilized on silica as a new stationary phase for
547 chromatographic modelling of skin permeation, *J. Pharm. Biomed. Anal.* 15 (1997) 1325–
548 1333. [https://doi.org/10.1016/S0731-7085\(96\)02009-2](https://doi.org/10.1016/S0731-7085(96)02009-2).
- 549 [18] M. Turowski, R. Kaliszan, Collagen immobilised on silica derivatives as a new stationary
550 phase for HPLC, *Biomed. Chromatogr.* 12 (1998) 187–192.
551 [https://doi.org/10.1002/\(SICI\)1099-0801\(199807/08\)12:4<187::AID-BMC727>3.0.CO;2-2](https://doi.org/10.1002/(SICI)1099-0801(199807/08)12:4<187::AID-BMC727>3.0.CO;2-2).
- 552 [19] M.J. Ruiz-Ángel, S. Carda-Broch, J.R. Torres-Lapasió, M.C. García-Álvarez-Coque, Retention
553 mechanisms in micellar liquid chromatography, *J. Chromatogr. A.* 1216 (2009) 1798–1814.
554 <https://doi.org/10.1016/j.chroma.2008.09.053>.
- 555 [20] J.J. Martínez-Pla, Y. Martín-Biosca, S. Sagrado, R.M. Villanueva-Camañas, M.J. Medina-
556 Hernández, Biopartitioning micellar chromatography to predict skin permeability, *Biomed.*
557 *Chromatogr.* 17 (2003) 530–537. <https://doi.org/10.1002/bmc.281>.
- 558 [21] J.J. Martínez-Pla, Y. Martín-Biosca, S. Sagrado, R.M. Villanueva-Camañas, M.J. Medina-
559 Hernández, Evaluation of the pH effect of formulations on the skin permeability of drugs by
560 biopartitioning micellar chromatography, *J. Chromatogr. A.* 1047 (2004) 255–262.
561 <https://doi.org/10.1016/j.chroma.2004.07.011>.
- 562 [22] L.J. Waters, Y. Shahzad, J. Stephenson, Modelling skin permeability with micellar liquid
563 chromatography, *Eur. J. Pharm. Sci.* 50 (2013) 335–340.
564 <https://doi.org/10.1016/j.ejps.2013.08.002>.
- 565 [23] V. Dobričić, K. Nikolic, S. Vladimirov, O. Čudina, Biopartitioning micellar chromatography as
566 a predictive tool for skin and corneal permeability of newly synthesized 17 β -carboxamide
567 steroids, *Eur. J. Pharm. Sci.* 56 (2014) 105–112. <https://doi.org/10.1016/j.ejps.2014.02.007>.
- 568 [24] A.W. Sobańska, J. Robertson, E. Brzezińska, Application of RP-18 TLC retention data to the
569 prediction of the transdermal absorption of drugs, *Pharmaceuticals.* 14 (2021) 147.
570 <https://doi.org/10.3390/ph14020147>.

- 571 [25] A.W. Sobańska, J. Robertson, E. Brzezińska, RP-18 TLC chromatographic and computational
572 study of skin permeability of steroids, *Pharmaceuticals*. 14 (2021) 600.
573 <https://doi.org/10.3390/ph14070600>.
- 574 [26] A.W. Sobańska, E. Brzezińska, RP-18 TLC and computational descriptors of skin permeability
575 of sunscreens, *Skin Pharmacol. Physiol.* 35 (2022) 174–179.
576 <https://doi.org/10.1159/000522366>.
- 577 [27] D.P. Poe, *Theory of Supercritical Fluid Chromatography*, in: C.F. Poole (Ed.), *Supercritical*
578 *Fluid Chromatography*, Elsevier, Amsterdam, The Netherlands, 2017: pp. 23–55.
- 579 [28] L. Nováková, A. Grand-Guillaume Perrenoud, I. Francois, C. West, E. Lesellier, D. Guillaume,
580 Modern analytical supercritical fluid chromatography using columns packed with sub-2 μ m
581 particles: A tutorial, *Anal. Chim. Acta.* 824 (2014) 18–35.
582 <https://doi.org/10.1016/j.aca.2014.03.034>.
- 583 [29] A. Tarafder, Metamorphosis of supercritical fluid chromatography to SFC: An Overview,
584 *Trends Anal. Chem.* 81 (2016) 3–10. <https://doi.org/10.1016/j.trac.2016.01.002>.
- 585 [30] C. Galea, D. Mangelings, Y. Vander Heyden, Characterization and classification of stationary
586 phases in HPLC and SFC - A review, *Anal. Chim. Acta.* 886 (2015) 1–15.
587 <https://doi.org/10.1016/j.aca.2015.04.009>.
- 588 [31] C.F. Poole, Stationary phases for packed-column supercritical fluid chromatography, *J.*
589 *Chromatogr. A.* 1250 (2012) 157–171. <https://doi.org/10.1016/j.chroma.2011.12.040>.
- 590 [32] C. West, E. Lemasson, S. Bertin, P. Hennig, E. Lesellier, An improved classification of
591 stationary phases for ultra-high performance supercritical fluid chromatography, *J.*
592 *Chromatogr. A.* 1440 (2016) 212–228. <https://doi.org/10.1016/j.chroma.2016.02.052>.
- 593 [33] C. Galea, D. Mangelings, Y. Vander Heyden, Method development for impurity profiling in
594 SFC: The selection of a dissimilar set of stationary phases, *J. Pharm. Biomed. Anal.* 111 (2015)
595 333–343. <https://doi.org/10.1016/j.jpba.2014.12.043>.

- 596 [34] Y. Grooten, A. Sych, D. Mangelings, Y. Vander Heyden, Comparison of in-silico modelling
597 and reversed-phase liquid chromatographic retention on an octadecyl silica column to predict
598 skin permeability of pharmaceutical and cosmetic compounds, *J. Pharm. Biomed. Anal.* 201
599 (2021) 114095. <https://doi.org/10.1016/j.jpba.2021.114095>.
- 600 [35] Y. Grooten, Q. Marcelis, D. Mangelings, Y. Vander Heyden, Evaluating micellar liquid
601 chromatographic methods on octadecyl particle-based and monolithic columns to predict the
602 skin permeation of drug and cosmetic molecules, *J. Chromatogr. A.* 1663 (2022) 462753.
603 <https://doi.org/10.1016/j.chroma.2021.462753>.
- 604 [36] Y. Grooten, D. Mangelings, Y. Vander Heyden, Predicting skin permeability of pharmaceutical
605 and cosmetic compounds using retention on octadecyl, cholesterol-bonded and immobilized
606 artificial membrane columns, *J. Chromatogr. A.* 1676 (2022) 463271.
607 <https://doi.org/10.1016/j.chroma.2022.463271>.
- 608 [37] C. Muscat Galea, A. Slosse, D. Mangelings, Y. Vander Heyden, Investigation of the effect of
609 column temperature and back-pressure in achiral supercritical fluid chromatography within the
610 context of drug impurity profiling, *J. Chromatogr. A.* 1518 (2017) 78–88.
611 <https://doi.org/10.1016/j.chroma.2017.08.008>.
- 612 [38] B.E. Vecchia, A.L. Bunge, Skin Absorption Databases and Predictive Equations, in: R.H. Guy,
613 J. Hadgraft (Eds.), *Transdermal Drug Delivery*, Marcel Dekker, New York, USA, 2003: pp.
614 57–141.
- 615 [39] I.T. Degim, W.J. Pugh, J. Hadgraft, Skin permeability data: anomalous results, *Int. J. Pharm.*
616 170 (1998) 129–133. [https://doi.org/10.1016/S0378-5173\(98\)00113-6](https://doi.org/10.1016/S0378-5173(98)00113-6).
- 617 [40] A.F. Azarbayjani, H. Lin, C.W. Yap, Y.W. Chan, S.Y. Chan, Surface tension and wettability in
618 transdermal delivery: a study on the in-vitro permeation of haloperidol with cyclodextrin across
619 human epidermis, *J. Pharm. Pharmacol.* 62 (2010) 770–778.
620 <https://doi.org/10.1211/jpp.62.06.0014>.

- 621 [41] J. Thomas, S. Majumdar, S. Wasdo, A. Majumdar, K.B. Sloan, The effect of water solubility of
622 solutes on their flux through human skin in vitro: an extended Flynn database fitted to the
623 Roberts-Sloan equation, *Int. J. Pharm.* 339 (2007) 157–167.
624 <https://doi.org/10.1016/j.ijpharm.2007.02.031>.
- 625 [42] K.T. Hoang, *Dermal Exposure Assessment: Principles and Applications*, Environmental
626 Protection Agency, Office of Health and Environmental Assessment, EPA/600/8–91/011B,
627 Washington, DC, USA, 1992.
- 628 [43] A. D’Attoma, C. Grivel, S. Heinisch, On-line comprehensive two-dimensional separations of
629 charged compounds using reversed-phase high performance liquid chromatography and
630 hydrophilic interaction chromatography. Part I: Orthogonality and practical peak capacity
631 considerations, *J. Chromatogr. A.* 1262 (2012) 148–159.
632 <https://doi.org/10.1016/j.chroma.2012.09.028>.
- 633 [44] A. Pedretti, L. Villa, G. Vistoli, VEGA - an open platform to develop chemo-bio-informatics
634 applications, using plug-in architecture and script programming, *J. Comput. Aided. Mol. Des.*
635 18 (2004) 167–173. <https://doi.org/10.1023/b:jcam.0000035186.90683.f2>.
- 636 [45] S. Kim, J. Chen, T. Cheng, A. Gindulyte, J. He, S. He, Q. Li, B.A. Shoemaker, P.A. Thiessen,
637 B. Yu, L. Zaslavsky, J. Zhang, E.E. Bolton, PubChem 2019 update: improved access to
638 chemical data, *Nucleic Acids Res.* 47 (2019) D1102–D1109.
639 <https://doi.org/10.1093/nar/gky1033>.
- 640 [46] VCCLAB (Virtual Computational Chemistry Laboratory), E-Dragon, (2005).
641 <http://www.vcclab.org> (accessed December 2, 2019).
- 642 [47] J.P.M. Andries, G.H. Tinnevelt, Y. Vander Heyden, Improved modelling for low-correlated
643 multiple responses by common-subset-of-independent-variables partial-least-squares, *Talanta.*
644 239 (2022) 123140. <https://doi.org/10.1016/j.talanta.2021.123140>.

- 645 [48] J.P.M. Andries, Y. Vander Heyden, L.M.C. Buydens, Improved variable reduction in partial
646 least squares modelling based on Predictive-Property-Ranked Variables and adaptation of
647 partial least squares complexity, *Anal. Chim. Acta.* 705 (2011) 292–305.
648 <https://doi.org/10.1016/j.aca.2011.06.037>.
- 649 [49] D.L. Massart, B.G.M. Vandeginste, L.M.C. Buydens, S. De Jong, P.J. Lewi, J. Smeyers-
650 Verbeke, *Handbook of Chemometrics and Qualimetrics, Part A*, Elsevier, Amsterdam, The
651 Netherlands, 1997.
- 652 [50] Q. Gros, J. Molineau, A. Noireau, J. Duval, T. Bamba, E. Lesellier, C. West, Characterization
653 of stationary phases in supercritical fluid chromatography including exploration of shape
654 selectivity, *J. Chromatogr. A.* 1639 (2021) 461923.
655 <https://doi.org/10.1016/j.chroma.2021.461923>.
- 656 [51] R.O. Potts, R.H. Guy, Predicting skin permeability, *Pharm. Res.* 9 (1992) 663–669.
657 <https://doi.org/10.1023/A:1015810312465>.
- 658 [52] B.G.M. Vandeginste, D.L. Massart, L.M.C. Buydens, S. De Jong, P.J. Lewi, J. Smeyers-
659 Verbeke, *Handbook of Chemometrics and Qualimetrics: Part B*, Elsevier, Amsterdam, The
660 Netherlands, 1998.
- 661